Targeted Gene Transfer to Fetal Rat Lung Interstitium by Ultrasound-guided Intrapulmonary Injection

Tiago Henriques‐Coelho, Sílvia Gonzaga, Masayuki Endo, Philip W. Zoltick, Marcus G. Davey, Adelino Leite‐Moreira, Jorge Correia‐Pinto, Alan W. Flake

Molecular Therapy · 2007 · 30 citations · 32 references

DOIFull text

Open access

Concepts

Abstract

In utero gene transfer to the developing lung may have clinical or research applications. In this study, we developed a new method for specifically targeting the fetal rat lung with adeno and lentiviral vectors encoding the enhanced green fluorescence protein (EGFP) marker gene at E15.5 using ultrasound biomicroscopy (UBM). Survival rate, morphometric parameters, viral biodistribution, and lung transduction efficiency were analyzed and compared to the intra-amniotic route of administration. Expression of EGFP started as early as 24 and 72 h after the injection of adenoviral and lentiviral vectors, respectively. Both vectors transduced lung parenchyma with gene expression limited to interstitial cells of the injected region, in contrast to intra-amniotic injection, which targeted the pulmonary epithelium. Expression of EGFP was most intense at E18.5 and E21.5 for adenoviral and lentiviral vectors, respectively. In contrast to lentivirus, adenoviral expression significantly declined until final analysis at 1 week of age. This study demonstrates the feasibility of targeting the fetal rat lung interstitium with viral vectors under UBM guidance during the pseudoglandular stage. This model system may facilitate in vivo studies of dynamic lung morphogenesis and could provide insight into the efficacy of prenatal gene transfer strategies for treatment of specific lung disorders. In utero gene transfer to the developing lung may have clinical or research applications. In this study, we developed a new method for specifically targeting the fetal rat lung with adeno and lentiviral vectors encoding the enhanced green fluorescence protein (EGFP) marker gene at E15.5 using ultrasound biomicroscopy (UBM). Survival rate, morphometric parameters, viral biodistribution, and lung transduction efficiency were analyzed and compared to the intra-amniotic route of administration. Expression of EGFP started as early as 24 and 72 h after the injection of adenoviral and lentiviral vectors, respectively. Both vectors transduced lung parenchyma with gene expression limited to interstitial cells of the injected region, in contrast to intra-amniotic injection, which targeted the pulmonary epithelium. Expression of EGFP was most intense at E18.5 and E21.5 for adenoviral and lentiviral vectors, respectively. In contrast to lentivirus, adenoviral expression significantly declined until final analysis at 1 week of age. This study demonstrates the feasibility of targeting the fetal rat lung interstitium with viral vectors under UBM guidance during the pseudoglandular stage. This model system may facilitate in vivo studies of dynamic lung morphogenesis and could provide insight into the efficacy of prenatal gene transfer strategies for treatment of specific lung disorders. IntroductionPrenatal gene transfer may offer a number of unique biological advantages relative to postnatal gene transfer.1Porada CD et al.Gestational age of recipient determines pattern and level of transgene expression following in utero retroviral gene transfer.Mol Ther. 2005; 11: 284-293Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar, 2Zanjani ED Anderson WF Prospects for in utero human gene therapy.Science. 1999; 285: 2084-2088Crossref PubMed Scopus (126) Google Scholar, 3Waddington SN Kennea NL Buckley SM Gregory LG Themis M Coutelle C Fetal and neonatal gene therapy: benefits and pitfalls.Gene Ther. 2004; 11: S92-S97Crossref PubMed Scopus (38) Google Scholar, 4Flake AW Stem cell and genetic therapies for the fetus.Semin Pediatr Surg. 2003; 12: 202-208Abstract Full Text Full Text PDF PubMed Scopus (13) Google Scholar The relatively high frequency and accessibility of stem cells and progenitors and their rapid proliferation in the fetus may offer efficiency advantages for stem-cell-targeted gene transfer. The low total cell number in the fetus allows relatively high vector to target cell ratios, allowing the use of small amounts of vector. The immunologic immaturity of the early gestational fetus may induce tolerance to vector-associated or transgene-encoded proteins. Finally, in utero gene transfer has the potential to treat a disease before its clinical manifestations. Advances in prenatal diagnosis of genetic and congenital disorders with progressively more sensitive techniques may increase opportunities for consideration of prenatal gene therapy.5Sylvester KG Yang EY Cass DL Crombleholme TM Adzick NS Fetoscopic gene therapy for congenital lung disease.J Pediatr Surg. 1997; 32: 964-969Abstract Full Text PDF PubMed Scopus (39) Google Scholar, 6Surbek DV Tercanli S Holzgreve W Transabdominal first trimester embryofetoscopy as a potential approach to early in utero stem cell transplantation and gene therapy.Ultrasound Obstet Gynecol. 2000; 15: 302-307Crossref PubMed Scopus (25) Google ScholarThe fetal lung is an attractive target organ for fetal gene transfer. There are a number of genetic and acquired disorders with peri- or postnatal pulmonary manifestations. These include monogenetic diseases like cystic fibrosis7Larson JE et al.Gene transfer into the fetal primate: evidence for the secretion of transgene product.Mol Ther. 2000; 2: 631-639Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar or surfactant protein B (SP-B) deficiency that would presumably require long-term expression of the deficient or defective gene. However, there are also abnormalities of lung growth, such as congenital diaphragmatic hernia, or lung maturation, such as respiratory distress syndrome of prematurity, that could potentially benefit from strategies that achieve transient gene expression in specific pulmonary distributions. Additionally, an important advantage of the use of non-integrating viral vectors with transient gene expression is the avoidance of many of the current concerns regarding integrating vectors in the fetus, i.e., insertional mutagenesis, developmental abnormalities, and germline alteration. We therefore anticipate the future need for a variety of lung-targeting strategies using different gene transfer technologies to achieve optimal therapeutic results.In this study, we describe a new method for the direct injection of viral vectors into the rat fetal lung as early as the pseudoglandular phase of lung development. Using this technique, we assessed the efficiency and distribution of transduction in the lung, the biodistribution of transduction, and the toxicity of equine infectious anemia virus (EIAV) and adenovirus vectors expressing the enhanced green fluorescence protein (EGFP) marker gene after in utero injection. In addition, we compare the direct injection technique to intra-amniotic injection with respect to the efficiency of lung transduction, and organ, and cellular distribution.ResultsThe technique of ultrasound-guided injectionsUltrasound biomicroscopy (UBM) was used to scan the fetus to identify the lung Figure 1). E15.5 was the earliest stage that we could perform in utero injections with a high survival rate and with accurate targeting of the developing lung. At E13.5 and E14.5, the lung bud was very difficult to visualize and mortality was unacceptably high. Important technical components of this procedure were the performance of a maternal laparotomy to expose the gravid uterus, and the application of pre-warmed sterile ultrasound gel over the uterus. This allowed manipulation of the fetal position into the axial orientation, which we found was the optimal plane for injection. The lung was best visualized between the level of the cardiac apex and upper part of the liver. Applying this imaging technique, we could inject small volumes (25–350 nL) of a viral vector suspension into the fetal lung parenchyma without any visually apparent injury to the lung or fetus. Injection of larger volumes was associated with the disruption of fetal lung architecture. The fetus and micropipette were manipulated so that the tip of the micropipette traversed only the uterine wall, amniotic membrane, amniotic cavity, fetal skin, and thoracic cavity (Figure 1 and Supplementary Video S1), avoiding the placenta, limbs, heart, or liver.Safety of in utero gene transferViral vectors used in this study were first-generation adenoviral vector and second-generation EIAV. To determine whether there was inherent toxicity from the viral preparation or from the early expression of the transgene, we compared survival after the intrapulmonary injection of viral vectors with injection of an equivalent volume of phosphate-buffered saline (PBS). The overall survival rate was 81±6, 82±5, and 87±4% for the PBS, EIAV, and adeno groups, respectively. Survival rates were calculated the of injected number of injected There was the at the and Survival Survival Survival Survival equine infectious anemia PBS, phosphate-buffered Survival is as of survival rate calculated the number of injected number of injected in a new In were used and were There were maternal There was evidence of transfer of vector or cells maternal was analyzed for EGFP maternal were analyzed in or at were and without parameters, and were and there were the 1). of the lung heart, and thoracic cavity was that until the after and of gene transfer to the lung and of gene determine the overall pattern of gene we used fluorescence intrapulmonary we that expression of with the volumes of was limited to the injected lung and the after intrapulmonary injection and Figure The of EGFP expression for the EGFP expression was as early as 24 h after injection for adenoviral vector the first expression until 72 h after injection for the lentiviral vector (Figure expression was at for adenovirus and at for the of lung EGFP fluorescence until was at the of the fluorescence was the of fluorescence was presumably to the of the lung and the relatively small of In the adenoviral expression of EGFP was also in in the and in the lung was in a vector biodistribution fluorescence the number of injected that were or for EGFP fluorescence at the were a of to for of enhanced green fluorescence EIAV, equine infectious anemia the number of injected that were or for EGFP fluorescence at the were a of to for of in a new Figure and lung for at E15.5 were analyzed at and of fluorescence of the at analysis after injection with lentiviral vector and adenoviral vector are vector transduction green fluorescence in an the of the injection. of for EGFP from the injected with lentiviral vector and adenoviral vector at the analysis are vector was only at with more EGFP expression at E21.5 and until vector an expression of EGFP with expression at EGFP expression was analyzed and vectors were in interstitial expression was Figure the fluorescence and to provide a of in gene expression over in the injected we (Figure of the number of vector lung the of the vector at in and adenoviral However, the number of vector was for adenoviral vector at and number progressively after number from gene transfer after E18.5 and was adenovirus at is important to that this is a direct of transduction efficiency between the viral vectors to the volumes and of adenoviral vector at a of was injected of vector at a of at the of volume allowed the there was at a of adenoviral vector However, this the fluorescence of the rapid in EGFP expression for over the between and In relatively were in the the of the for of vector in lung after PBS, and lentiviral at different of of vector in and lung after PBS, and lentiviral injections at lung of injected compared to Figure of viral that EGFP gene expression was relatively limited to the lung after injection and to more assessed gene expression in the injected we at E21.5 (Figure number of vector relative to were in the and in the of the micropipette the thoracic in the and there were in EGFP expression the distribution of gene transduction the cells were found in the pulmonary interstitium for the and adenoviral groups, after intrapulmonary injections (Figure There was expression of gene in the of or in the cells for a cell marker (Figure and for a surfactant protein in (Figure and and Supplementary Figure we that transduced cells were the interstitial of the lung and that were This is in contrast to the expression with intra-amniotic vector injections (Figure and of cells after injection. for EGFP and in injected with lentiviral and adenoviral were at for EGFP and for an of and at and for and respectively. were with and for and to optimal of before manipulation in Supplementary Figure cells with or and were the interstitial of the of transduced cells after intra-amniotic injection. injections were at and the were at and lung for EGFP are the transduction of only Figure for the first the feasibility of using UBM to perform in utero intrapulmonary injections in at the pseudoglandular stage of lung development. Both adenoviral and lentiviral vectors transduced lung different expression were following injection. adenoviral vector expression and was lentiviral vector expression was relatively and the of this in contrast to intra-amniotic vectors transduced interstitial cells and or or of vector have to achieve prenatal gene transfer to the lung SM et transduction in fetal Ther. 2005; 12: Full Text Full Text PDF PubMed Scopus Google Scholar, B of an adenoviral vector for gene transfer to fetal and PubMed Scopus Google Scholar, In utero gene transfer to pulmonary Ther. Full Text Full Text PDF PubMed Scopus Google Scholar, JE In utero virus gene transfer in and 2003; Scholar S C expression following in utero gene Ther. 1999; PubMed Scopus Google Scholar, S et transgene expression in cardiac and following fetal of adenoviral or viral vectors in 2003; PubMed Scopus Google Scholar, SN et transgene expression of a vector to the fetal of Ther. 2003; PubMed Scopus Google Scholar gene transfer to the respiratory of fetal in Ther. PubMed Scopus Google Scholar, et and marker gene expression in the of fetal after application of adenovirus in Ther. 2004; 11: PubMed Scopus Google Scholar, ED in vivo gene transfer to the in fetal Pediatr Surg. 2005; Full Text Full Text PDF PubMed Scopus Google Scholar and et vector gene transfer into fetal lung-targeting Ther. Full Text Full Text PDF PubMed Scopus Google Scholar, et and gene transfer in and efficiency of lentiviral vectors for fetal gene Ther. 2005; 12: Full Text Full Text PDF PubMed Scopus Google Scholar and the of for fetal lung. and intrapulmonary more specific to the lung, have only in et et vector gene transfer into fetal lung-targeting Ther. Full Text Full Text PDF PubMed Scopus Google Scholar in a that intrapulmonary injections during the pseudoglandular stage allowed specific targeting of the lung relative to injections during the stage. In this study, we used UBM to perform in utero intrapulmonary The use of this relatively new imaging injection of the fetal rat lung at UBM ultrasound for imaging and allowing and has for fetal analysis of early PubMed Scopus Google Scholar, Advances in ultrasound 2000; Full Text Full Text PDF PubMed Scopus Google Scholar Using we could target the rat lung during the of the pseudoglandular stage of lung with a high fetal survival adenovirus and vectors were used in this We to study first-generation adenoviral vectors viral vectors we to expression of the marker gene. We used to the that human lentiviral vectors have high efficiency W et to virus 1999; Google Scholar, C in gene transfer and over therapeutic 2000; PubMed Scopus Google Scholar in many and to the application of vectors in fetal et SN et transgene expression of a vector to the fetal of Ther. 2003; PubMed Scopus Google Scholar has of the most viral of its high transduction rapid of transgene and high C in gene transfer and over therapeutic 2000; PubMed Scopus Google Scholar, M et in utero gene transfer in and distribution of adenovirus 2000; Full Text PDF PubMed Scopus (49) Google Scholar, B et gene transfer for human gene Ther. PubMed Scopus Google Scholar, of gene therapy for lung 2003; PubMed Scopus Google Scholar The with adenovirus is its high and to We that this is a with in gestational fetal in the is with adenoviral during the phase of immunologic EY Cass DL KG Adzick NS Fetal gene therapy: and immunologic of early of Pediatr Surg. 1999; Full Text PDF PubMed Scopus (38) Google Scholar as we would from the stage of rat at we in the lung in However, as the of this study was of we perform a analysis of to adenoviral or In contrast to lentiviral vectors are relatively and and transgene into and cells with long-term gene et vivo gene and transduction of cells a lentiviral PubMed Scopus Google Scholar, lentiviral vector gene in 1997; 15: PubMed Scopus Google Scholar, M S Crombleholme AW of high vector 2004; PubMed Scopus Google Scholar The are the low that are in C in gene transfer and over therapeutic 2000; PubMed Scopus Google Scholar This in the current vector of only infectious we to inject the volume of of to achieve rapid of EGFP expression in the is in with the of adenoviral gene the small volume of vector and the rapid proliferation of fetal lung are also with the of to transgene into the In the there a increase in number at We would from this analysis that adenovirus would the most vector to use the is to induce rapid and transient of a gene in this would a more vector to induce and long-term gene transfer was to the injected lung with the only the the and a very low number in the This could to injection of the is more to the small of injection associated with this EGFP expression analysis in the or However, in the for have gene This amounts of of the vector into the amniotic during of the The of pulmonary transduction in intra-amniotic is most the very volume of into the amniotic relative to the volume of in the intra-amniotic injection as as the of the injection. In and that of SM et transduction in fetal Ther. 2005; 12: Full Text Full Text PDF PubMed Scopus Google Scholar transduction efficiency of pulmonary after the intra-amniotic of vector is limited to a gestational to the of fetal respiratory In this study, intrapulmonary injections were 1 before the transduction to pulmonary is after intra-amniotic of the most in study was the for the interstitial with the vectors There was expression of gene in the of or in the The of cells was we were to identify the cells in this study to a of specific for cell in the we that the cells were in with a and to EGFP with a surfactant protein in that the transduced cells were and that were the interstitial of the lung. This is in contrast to the expression with intra-amniotic vector the is the route of injection, the tip of lung parenchyma and and would to transduction as We have an for this was in and with vectors In in the studies of direct lung transduction in using human lentiviral et vector gene transfer into fetal lung-targeting Ther. Full Text Full Text PDF PubMed Scopus Google Scholar, et and gene transfer in and efficiency of lentiviral vectors for fetal gene Ther. 2005; 12: Full Text Full Text PDF PubMed Scopus Google Scholar only expression was so this to a of the of cells that were transduced require to this is the first of this pattern of expression with any of prenatal lung gene transfer. The of transduction of cell the lung with different of transduction the of gene expression in specific and cell the developing lung. This may have during the pseudoglandular phase of lung to achieve gene transfer direct intrapulmonary injection in a rat model a for the of potential therapeutic strategies for lung disorders and for biological studies the of specific lung development. advantages of this technique include of to the the of of human lung of the and of cystic PubMed Scopus Google Scholar, The rat in the study of cystic and PubMed Scopus Google Scholar, et congenital diaphragmatic in Pediatr Surg. Full Text PDF PubMed Scopus Google Scholar this study was in we also have with this approach in with Finally, the of targeting the lung during the pseudoglandular stage may unique clinical This intense is the of overall of the and of the fetal lung, and to a stage of immunologic immaturity and of gene transfer during this has the potential to have the of lung with potential for and were the and at the of and in the of for the and of vector vector the EGFP gene from an The and the transfer transfer vectors from equine infectious anemia Ther. PubMed Scopus Google Scholar, M of gene transfer and expression in using enhanced Ther. 2003; Full Text Full Text PDF PubMed Scopus Google Scholar were The the infectious anemia virus protein viral and Google Scholar was The transfer was the and and the was after the et of and at the of the equine infectious anemia virus 1999; PubMed Scopus Google Scholar virus were and with the JE JE virus a Google Scholar vector with the virus was in cells as lentiviral vector gene in 1997; 15: PubMed Scopus Google Scholar The M to a total volume of to of The vector were at for at were from 1 to 1 infectious human under the human and was from the vector of the of of S et transgene expression in cardiac and following fetal of adenoviral or viral vectors in 2003; PubMed Scopus Google Scholar vectors were as Scholar, of adenoviral PubMed Scopus (27) Google Scholar, of first-generation adenoviral Google Scholar vector was at in with vector were in at a of infectious vectors administration. at were with for for and a The was a and at The was and was and the or was and with a pre-warmed sterile ultrasound gel were to axial of the in using a were with to the micropipette that was to a with the or viral vector suspension and with the the micropipette tip was the uterine and amniotic cavity into the lung and a specific volume was The micropipette was and the fetus was and the procedure was and were injected The of the procedure maternal and its was The was and in a were at E21.5 and or were for the of abnormalities and lung, and were were for and at were as laparotomy was and of the was at a The injections were under direct with to a were with adenovirus suspension and were injected into the intra-amniotic cavity of fetus. of the procedure was the was in and in a were at E21.5 and were for were visualized under fluorescence after to EGFP transduction and biodistribution of the vector. of the fetus from the amniotic the and were for was and the and were The and of the were also and for and were in in and with and To and EGFP protein in the were and in in were for specific protein with and with were for with with were with developed with the and with of and were with with at and with were with with at and with were with visualized under the to the distribution of and the of and for and was using the techniques were with with and were to the in Figure and from the injected were at and were at E21.5 and the heart, skin, and for were in and at was from using the were the were from the for the vector and for of The of were at the with the and at the with the The and for the were as The was The system an with and of and as were for at at at for and for 1 The were in a final volume of 1 of the of and of the was in the for was with from to In the the calculated was for as were analyzed in were analyzed the system analysis of The were as To the of the in the of transduction in at different analysis of was between were to with Supplementary 1 and with Video Fetal lung injections with Figure and of the in Figure and IntroductionPrenatal gene transfer may offer a number of unique biological advantages relative to postnatal gene transfer.1Porada CD et al.Gestational age of recipient determines pattern and level of transgene expression following in utero retroviral gene transfer.Mol Ther. 2005; 11: 284-293Abstract Full Text Full Text PDF PubMed Scopus (27) Google Scholar, 2Zanjani ED Anderson WF Prospects for in utero human gene therapy.Science. 1999; 285: 2084-2088Crossref PubMed Scopus (126) Google Scholar, 3Waddington SN Kennea NL Buckley SM Gregory LG Themis M Coutelle C Fetal and neonatal gene therapy: benefits and pitfalls.Gene Ther. 2004; 11: S92-S97Crossref PubMed Scopus (38) Google Scholar, 4Flake AW Stem cell and genetic therapies for the fetus.Semin Pediatr Surg. 2003; 12: 202-208Abstract Full Text Full Text PDF PubMed Scopus (13) Google Scholar The relatively high frequency and accessibility of stem cells and progenitors and their rapid proliferation in the fetus may offer efficiency advantages for stem-cell-targeted gene transfer. The low total cell number in the fetus allows relatively high vector to target cell ratios, allowing the use of small amounts of vector. The immunologic immaturity of the early gestational fetus may induce tolerance to vector-associated or transgene-encoded proteins. Finally, in utero gene transfer has the potential to treat a disease before its clinical manifestations. Advances in prenatal diagnosis of genetic and congenital disorders with progressively more sensitive techniques may increase opportunities for consideration of prenatal gene therapy.5Sylvester KG Yang EY Cass DL Crombleholme TM Adzick NS Fetoscopic gene therapy for congenital lung disease.J Pediatr Surg. 1997; 32: 964-969Abstract Full Text PDF PubMed Scopus (39) Google Scholar, 6Surbek DV Tercanli S Holzgreve W Transabdominal first trimester embryofetoscopy as a potential approach to early in utero stem cell transplantation and gene therapy.Ultrasound Obstet Gynecol. 2000; 15: 302-307Crossref PubMed Scopus (25) Google ScholarThe fetal lung is an attractive target organ for fetal gene transfer. There are a number of genetic and acquired disorders with peri- or postnatal pulmonary manifestations. These include monogenetic diseases like cystic fibrosis7Larson JE et al.Gene transfer into the fetal primate: evidence for the secretion of transgene product.Mol Ther. 2000; 2: 631-639Abstract Full Text Full Text PDF PubMed Scopus (49) Google Scholar or surfactant protein B (SP-B) deficiency that would presumably require long-term expression of the deficient or defective gene. However, there are also abnormalities of lung growth, such as congenital diaphragmatic hernia, or lung maturation, such as respiratory distress syndrome of prematurity, that could potentially benefit from strategies that achieve transient gene expression in specific pulmonary distributions. Additionally, an important advantage of the use of non-integrating viral vectors with transient gene expression is the avoidance of many of the current concerns regarding integrating vectors in the fetus, i.e., insertional mutagenesis, developmental abnormalities, and germline alteration. We therefore anticipate the future need for a variety of lung-targeting strategies using different gene transfer technologies to achieve optimal therapeutic results.In this study, we describe a new method for the direct injection of viral vectors into the rat fetal lung as early as the pseudoglandular phase of lung development. Using this technique, we assessed the efficiency and distribution of transduction in the lung, the biodistribution of transduction, and the toxicity of equine infectious anemia virus (EIAV) and adenovirus vectors expressing the enhanced green fluorescence protein (EGFP) marker gene after in utero injection. In addition, we compare the direct injection technique to intra-amniotic injection with respect to the efficiency of lung transduction, and organ, and cellular

References

32